Indication
Stage I Small Lymphocytic Lymphoma
6 clinical trials
10 products
10 drugs
Clinical trial
A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
TafasitamabDrug
lenalidomideClinical trial
Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic FeaturesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
LenalidomideClinical trial
A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)Status: Completed, Estimated PCD: 2018-04-04
Product
curcuminClinical trial
A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell TransplantStatus: Completed, Estimated PCD: 2024-02-02
Clinical trial
Rituximab For Prevention Of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)Status: Terminated, Estimated PCD: 2012-12-19
Drug
rituximabDrug
tacrolimusProduct
Anti-thymocyte globulinDrug
cyclophosphamideProduct
FludarabineDrug
busulfanProduct
Immunosuppressive therapyClinical trial
Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell LymphomasStatus: Active (not recruiting), Estimated PCD: 2023-07-29
Drug
etoposideDrug
prednisoneDrug
VincristineProduct
Doxorubicin